Multicenter Web-based phase III study to test the survival equivalence of non-platinum-based (NPB) vs platinum-based (PB) therapy for advanced non-small cell lung cancer (NSCLC): The Dartmouth NPB Chemotherapy Trial (D0112)

Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials

“…Eighteen potentially relevant trials were identified through literature analysis (10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(26)(27)(28)(29). Three phase II studies [26][27][28] and a phase III study exclusively published in Chinese [29] were excluded ( Fig.…”

Combination of chemotherapy without platinum compounds in the treatment of advanced non-small cell lung cancer: A systematic review of phase III trials

“…Hitherto, the clinical benefit for the patient is unclear. Actually, all retrieved randomised phase III studies but one [31] were designed with a superiority hypothesis for median survival [19,24,25], 1-year survival [20,29,30], progression-free survival [32,33] or quality of life [21] in favour of the non-platinum regimens. The statistical design is unknown in two cases [22,26].…”

“…The third study randomly assigned the patients between a carboplatin arm (AUC 6 mg ml −1 min −1 ) associated with docetaxel (75 mg/m 2 ) and a platinum-free regimen combining docetaxel and gemcitabine [31]. The preliminary results of this ongoing study demonstrated nearly similar 1-year survival rate of 45% and 42%, respectively.…”

NSCLC—platinum or not

“…However, the reported studies are not powered to address the question of equivalence of the two chemotherapy combinations. One such study testing the survival equivalence of non-platinum-based and platinumbased therapy has just been reported [25]. At the predefined interim analysis, there was no statistical survival advantage for platinum or non-platinumbased therapy and the study is currently ongoing.…”